MacIntyre I, Stevenson J C, Whitehead M I, Wimalawansa S J, Banks L M, Healy M J
Endocrine Unit, Royal Postgraduate Medical School, London.
Lancet. 1988 Apr 23;1(8591):900-2. doi: 10.1016/s0140-6736(88)91712-6.
A 2-year randomised pilot study was conducted in 70 patients to see whether the osteoclast-inhibiting effect of calcitonin would reduce postmenopausal vertebral bone loss. An oestradiol-treated group was included in the study as a positive control since oestrogens are known to be effective. Calcitonin reduced vertebral bone loss in doses above 250 micrograms human calcitonin (50 international units) a week, and at this dose was as effective as oestradiol.
对70名患者进行了一项为期2年的随机试点研究，以观察降钙素抑制破骨细胞的作用是否会减少绝经后椎体骨质流失。由于已知雌激素有效，因此研究中纳入了一个接受雌二醇治疗的组作为阳性对照。降钙素每周剂量高于250微克人降钙素（50国际单位）时可减少椎体骨质流失，且在此剂量下与雌二醇效果相同。
